SLIMamp Overview

Simplified

    • Single-well amplification
    • Minimal sample required
      • As little as 2.5 ng FFPE DNA sample (solid tumor assays)
      • 20 ng circulating tumor DNA (liquid biopsy)
 
  • Germline, Somatic, and ctDNA Panels available
  • Compatible with existing liquid handlers
  • DNA to Sequencer in <8 hours without time consuming ligation steps
 

Robust

  • Uniform sequencing coverage of target regions with very high mapping and on-target rates (typically exceeding 98%)
  • High reproducibility eliminates sample re-runs

Cost-Effective

  • High mapping and on-target rates efficiently utilizes sequencing capacity
  • Labor-saving workflow saves valuable technician time
  • Eliminate sample failure and need to re-run due to insufficient DNA quantity
  • Attractive pricing

SLIMamp Overlapping Multiplex PCR Technology

Pillar Biosciences’ patented SLIMamp (Stem-Loop Inhibition-Mediated amplification) technology enables specific priming of overlapping target segments.*

*For further details, see the reference “Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2” by Schenk D, Song G, Ke Y, Wang Z. PLoS One. 2017 Jul 12;12(7):e0181062. doi:10.1371/journal.pone.0181062. PMID: 28704513 for both technical details as well as performance data on BRCA1 and BRCA2 with known mutation status.

SLIMamp Performance Data

Below are the sequencing results of 34 samples sequenced with the ONCOReveal BRCA1 & BRCA2 Panel.

ONCOReveal BRCA Variant Statistics

A
Unique Variants
Type Count Notes
Insertion 4 1 bp
Deletion 4 1-4 bp, 11 bp, and 40 bp
SNV 47
Total 66
B
Variant Detection from 34 unique samples with full ROI region validated by at least one independent method
Variant Detected Variant not Detected
True Positive (TP) 409 Heterozygous SNVs 234 False Negative (FN) 0
Homozygous SNVs 153
Heterozygous INDELS (1-40 bp) 22
False Positive (TP) 0 True Negative (TN)* 603737
*TN= Size of ROI (17769 bp) x Total Samples (34) - Total True positives in all samples
C
Analytical sensitivity and specificity
Statistic Formula Value 95% Cl
Sensitivity TP/(TP+FN) 100.00% 99.10% to 100.00%
Specificity TN/(TN+FP) 100.00% 100.00% to 100.00%
A
Unique Variants
Type Count Notes
Insertion 4 1 bp
Delection 4 1-4 bp, 11 bp, and 40 bp
SNV 47
Total 66
B
Variant Detection from 34 unique samples with full ROI region validated by at least one independent method
Variant Detected Variant not Detected
True Positive (TP) 409 Heterozygous SNVs 234 False Negative (FN) 0
Homozygous SNVs 153
Heterozygous INDELS (1-40 bp) 22
False Positive (TP) 0 True Negative (TN)* 603737
*TN= Size of ROI (17769 bp) x Total Samples (34) - Total True positives in all samples
C
Analytical sensitivity and specificity
Statistic Formula Value 95% Cl
Sensitivity TP/(TP+FN) 100.00% 99.10% to 100.00%
Specificity TN/(TN+FP) 100.00% 100.00% to 100.00%
 
For further details on the samples and methods used to generate this dataset, refer to this PLoS publication.

ONCOReveal BRCA1 & BRCA2 Panel Shows High Target Coverage with SLIMamp

The Pillar SLIMamp enrichment technology provides outstanding and highly reproducible coverage of target regions even with limited sample input.
  Coverage >20% and >30% of the Mean: 4 replicates and 3 input amounts  

Varying amounts of a BRCA reference standard were used to generate sequencing libraries (5 ng, 10 ng and 20 ng of Horizon Diagnostics HD793 and HD795 reference standards) and sequenced in triplicate. A total of 12 samples were sequenced at a mean coverage of 4800x, and the average coverage of the target at >20% of the mean was 99.67%.